This website is intended for UK healthcare professionals only Log in | Register

Tag Archives: low-density lipoprotein

May 2019 Br J Cardiol 2019;26:52

In briefs

BJC Staff

Abstract

Stat tests loaded into the VITROS XT 7600 Moderate alcohol consumption does not protect against stroke Blood pressure and stroke risk increase steadily with increasing alcohol intake, and previous claims that one to two alcoholic drinks a day might protect against stroke are not borne out by new evidence from a genetic study involving 160,000 adults. Studies of East Asian genes, where two common genetic variants strongly affect what people choose to drink, show that alcohol itself directly increases blood pressure and the chances of having a stroke, according to a new study published in The Lancet (doi: 10.1016/S0140-6736(18)31772-0). Researc

| Full text

October 2017

ESC 2017: CANTOS – a focus on inflammation and atherosclerosis

Chris Allen

Abstract

Atherosclerosis has long been characterised as a chronic inflammatory condition. Elevation of the non-specific inflammatory marker high sensitivity c-reactive protein (hs-CRP) is an accepted predictor of adverse cardiovascular events and its reduction in JUPITER (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) and other statin trials has been linked with improved outcomes, even with low-density lipoprotein (LDL) cholesterol levels within the normal range.1 Although a specific aetiological link has proven harder to delineate, the cytokine interleukin 1β (IL-1β), pro-inflammatory messenger of

| Full text

October 2017

ESC 2017: REVEAL – modest beneficial effects with anacetrapib

BJC Staff

Abstract

Presented in a hotline session by Dr Martin Landray (University of Oxford), the trial’s co-principal investigator, and simultaneously published in the New England Journal of Medicine (https://doi.org/10.1056/NEJMoa1706444), this large-scale, placebo-controlled study was carried out on 30,449 patients with cardiovascular disease, who were all receiving lipid-lowering treatment with atorvastatin. Those patients also receiving anacetrapib (100 mg once daily) showed a significant reduction in the primary outcome, the risk of major coronary events (coronary death, myocardial infarction or coronary re-vascularisation) by 9% relative to those pati

| Full text

October 2017

ESC 2017: PURE shows we should revisit dietary fat guidelines

BJC staff

Abstract

Results from the PURE (Prospective Urban-Rural Epidemiology) study, carried out on 135,000 individuals aged 35 to 70 years from 18 low, middle and high-income countries (North America, Europe, South America, the Middle East, South Asia, China, South East Asia and Africa) has contrasted with current dietary advice, by finding that high carbohydrate intake is linked to worse total mortality and non-cardiovascular mortality outcomes, while high fat intake is associated with lower risk. “Our findings do not support the current recommendation to limit total fat intake to less than 30% of energy and saturated fat intake to less than 10% of energ

| Full text

March 2008 Br J Cardiol 2008;15:79–81

Familial hypercholesterolaemia: recognising the unrecognised

Jonathan Morrell

Abstract

(more…)

| Full text

March 2008 Br J Cardiol 2008;15:83-85

Low-density lipoprotein-apheresis: an update

Stefanos Archontakis, Alison Pottle, Mahmoud Barbir

Abstract

Indications, techniques and effects Low density lipoprotein (LDL)-apheresis is a selective lipid-lowering extracorporeal treatment where LDL and other atherogenic apoB-lipoproteins are removed from circulation while high-density lipoprotein (HDL) remains virtually unchanged. In the last years, individual authors as well as various scientific organisations have proposed different indications for using LDL-apheresis. The most widely used guidelines are those of the Food and Drug Administration (FDA) in the USA,1 of the Federal Committee of Physicians and Health Insurance Funds in Germany2 and recently, those of the International Panel on the M

| Full text

January 2008 Br J Cardiol 2008;15:7-11

UK approves testing embryos for FH

BJCardio editorial team

Abstract

FH is caused by a single gene defect on chromosome 19. Individuals with two copies of the defective gene have severely raised low-density lipoprotein (LDL) cholesterol levels from birth and are predisposed to early atherosclerosis. Many die in childhood, and most suffer at least one myocardial infarction by the end of their 20s. The milder, heterozygous form of FH is much more common and can be managed using a combination of diet and drugs. The couple for whom the licence has been awarded discovered that they were both heterozygous for FH only after having their first child who is homozygous for FH. The pre-implantation diagnosis will involve

| Full text

November 2006 Br J Cardiol 2006;13:379-81

An unacceptable level of cardiovascular risk still remains prevalent in the UK – are we doing enough?

M John Chapman

Abstract

No content available

| Full text

March 2006 Br J Cardiol 2006;13:131-6

The failure of LDL cholesterol reduction and the importance of reverse cholesterol transport. The role of nicotinic acid

H Robert Superko

Abstract

No content available

| Full text
Close

You are not logged in

You need to be a member to print this page.
Find out more about our membership benefits

Register Now Already a member? Login now
Close

You are not logged in

You need to be a member to download PDF's.
Find out more about our membership benefits

Register Now Already a member? Login now